// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
B
Personalized neoantigen mRNA vaccines reduce melanoma recurrence post-resection
KEYNOTE-942 phase 2 (mRNA-4157 + pembrolizumab) HR ~0.56; phase 3 ongoing.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →